Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-04-22

FDA Approved: EVOTAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)

View source ↗

Summary

The FDA approved a supplemental application for EVOTAZ (atazanavir/cobicistat) submitted by E.R. Squibb & Sons, L.L.C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EVOTAZ (atazanavir and cobicistat)

Snippet

SUPPL AP for EVOTAZ (ATAZANAVIR AND COBICISTAT)